Loading research and source information…
Parkinson’s disease · Drug research
The registry reports completed. This is trial metadata, not an assessment of treatment benefit.
Evidence 1Content updated Oct 27, 2026 · Sources last checked Oct 27, 2026
Inclusion Criteria: 1. Male/female patients with early Parkinson's disease who are over 30 years old and under 75 years old (including cut-off values). 2. Able to understand and willing to sign an informed consent form (ICF) voluntarily. 3. The diagnosis of Parkinson's disease complies with idiopathic Parkinson's disease (2015 version of MDS Parkinson's disease diagnostic criteria). 4. Modified Hoehn and Yahr Scale≥1, ≤2.5 points. 5. Agree to use medically acceptable contraceptive methods throughout the study and within 1 month after completing the study. Exclusion Criteria: 1. Have a history of severe allergic reactions or allergies to levodopa or carbidopa. 2. Pregnancy or breastfeeding. 3. Diagnosed as atypical Parkinson's disease or any known secondary Parkinson's syndrome. 4. The investigator believes that the placebo treatment cannot be tolerated. 5. Acute psychosis or hallucinations, using any antipsychotic to treat psychosis or clinically obvious depression. 6. History of epilepsy or epilepsy. 7. The history of narrow-angle glaucoma. 8. Subjects with a history of malignant melanoma. 9. Patients with obvious cognitive impairment. 10. The investigator believes that there are clinically significant medical or surgical diseases and patients who are not suitable for participating in clinical trials.
This record covers only the linked trial population. This registry-based page does not review FDA approval or labeling.
FDA approval not reviewed here
Parkinson’s disease
See FDA labeling for the approved population and indication; this page covers the trial population only.
FDA labeling has not been reviewed for this page. This does not mean the treatment is unapproved.
Approval is specific to the indication and population. It does not establish availability, reimbursement or suitability for an individual.
This study has ended. Completion alone does not show that a treatment works.
Read trial record and posted resultsStudy ages: 30 Years to 75 Years. Other eligibility criteria apply; see the full criteria above.
Study countries and territories (including sites that may be closed): China.
Primary data collection: Dec 28, 2022 (actual). This is not a results-release date.
Results posted Oct 7, 2026
Evidence 1registry · Registry metadata is submitted by the sponsor or responsible party and does not independently validate efficacy.
Results are posted in the registry. Outcomes have not been appraised in this record.
Limitations: Outcomes, effect estimates, uncertainty and study quality have not been appraised. Consult original results and publications.
Evidence 1A Study of the Efficacy and Safety of Carbidopa-Levodopa Extended-Release Tablets in Patients With Parkinson's Disease
registry · NCT05036473 · Structured source fields
Source date: Oct 7, 2026 · Checked: Oct 27, 2026
Evidence location: protocolSection: identificationModule, statusModule, conditionsModule, armsInterventionsModule, designModule, outcomesModule, eligibilityModule, contactsLocationsModule, sponsorCollaboratorsModule; hasResults
Status: COMPLETED. Phase: PHASE2. Conditions: Parkinson Disease.
Open original source